Combination of Brachytherapy and Intravitreal Chemotherapy in the Treatment of Retinoblastoma with Vitreous Seeding
Open Access
- 30 November 2021
- journal article
- research article
- Published by S. Karger AG in Ocular Oncology and Pathology
- Vol. 8 (1) , 64-70
Abstract
Purpose: The aim of this study was to report the efficacy of combined intravitreal chemotherapy (IVC) and ruthenium-106 brachytherapy in retinoblastoma, either as first-line or second-line treatment, following systemic chemoreduction or intra-arterial chemotherapy. Methods: Retrospective data of 18 eyes from 18 patients treated with IVC and brachytherapy from August 2014 to December 2019 were collected. Results: The method described was our first-line therapy in 6 patients, whereas it was used as second-line treatment after chemoreduction in the remaining 12 patients. The eyes showed the following classification at initial presentation: 2 group B eyes, 3 group C eyes, and 13 group D eyes. The mean follow-up was 19.5 months (range 2–53 months). The mean patient age at brachytherapy was 34.0 months (range 15–83 months). The median prescribed dose at the tumour base and apex was 574.5 ± 306.7 Gy and 88.5 ± 12.2 Gy, respectively. The ocular retention rate was 66.7%. Six eyes had to be enucleated due to uncontrollable subretinal and recurrent vitreous seeding, tumour relapse, recurrence of a solid tumour elsewhere in the eye, and persistent vitreous bleeding with loss of tumour control. The mean number of intravitreal injections of melphalan was 5.0. Two patients received a simultaneous injection of topotecan for insufficient therapeutic response. With regard to radiogenic complications, we could observe temporary retinal and vitreous bleeding (27.8%), serous retinal detachment (44.4%), and radiogenic maculopathy and retinopathy (11.1%). None of the children showed metastatic disease during follow-up. Conclusion: Ruthenium-106 plaque therapy in combination with IVC is an effective local therapy with good tumour control rates even in advanced eyes. Overall, the analysed therapeutic approach shows an acceptable side-effect profile, especially when considering that external-beam radiation therapy and systemic polychemotherapy or at least the number of cycles needed, with their increased incidence of adverse events, can thus be avoided.Keywords
This publication has 22 references indexed in Scilit:
- The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastomaBrachytherapy, 2014
- Salvage/Adjuvant Brachytherapy After Ophthalmic Artery Chemosurgery for Intraocular RetinoblastomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- 106Ruthenium Plaque Therapy (RPT) for RetinoblastomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indicationsBritish Journal of Ophthalmology, 2012
- Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle trackBritish Journal of Ophthalmology, 2012
- Published International Classification of Retinoblastoma (ICRB) Definitions Contain Inconsistencies—An Analysis of ImpactOphthalmic Genetics, 2009
- Iodine 125 Plaque Radiotherapy as Salvage Treatment for Retinoblastoma Recurrence after Chemoreduction in 84 TumorsOphthalmology, 2006
- β-Ray brachytherapy with 106Ru plaques for retinoblastomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- The treatment of ophthalmic tumours with low-energy sourcesBritish Journal of Radiology, 1976
- RETINAL GLIOMATA TREATED BY RADON SEEDSBritish Journal of Ophthalmology, 1931